People with pulmonary hypertension (PH) face significant obstacles when seeking timely care, with barriers arising at each stage from…
Articles by Steve Bryson, PhD
Tectonic Therapeutic plans to launch a Phase 2 clinical trial to test the impact of its therapy candidate TX45…
Having pulmonary hypertension (PH) increases the risk of death, both in the short and long term, for individuals undergoing…
People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates…
Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the…
Beyond Air has submitted a supplement application to the U.S. Food and Drug Administration (FDA) for its LungFit PH…
Low-dose metformin, a medication for type 2 diabetes, delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of…
Treatment with Opsynvi (macitentan and tadalafil) as a single-tablet combination therapy for people with pulmonary arterial hypertension (PAH)…
A higher diameter ratio on CT scans between the right ventricle and left ventricle, which are the heart’s lower chambers,…
Boosting the production of a protein called myotubularin-related protein 7 (MTMR7) reversed signs of pulmonary arterial hypertension (PAH) in…
Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of…
Cereno Scientific‘s investigational oral therapy CS1 improves right heart function in people with pulmonary arterial hypertension (PAH), according…